Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
0.80% $25.12
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 170.95 mill |
EPS: | -4.00 |
P/E: | -6.28 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 46.61 mill |
Avg Daily Volume: | 0.602 mill |
RATING 2024-03-27 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -6.28 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.07x |
Company: PE -6.28 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 23.95 - 26.29 ( +/- 4.67%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Bjerkholt Eric | Buy | 2 000 | Common Stock |
2024-03-25 | Radovich Peter | Sell | 4 303 | Common Stock |
2023-01-09 | Radovich Peter | Sell | 1 379 | Common Stock |
2023-01-09 | Vig Pamela | Sell | 1 379 | Common Stock |
2019-09-10 | Longpre Lara | Buy | 965 | Common Stock |
INSIDER POWER |
---|
-83.48 |
Last 98 transactions |
Buy: 1 143 723 | Sell: 16 296 571 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $25.12 (0.80% ) |
Volume | 0.388 mill |
Avg. Vol. | 0.602 mill |
% of Avg. Vol | 64.44 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $27.19 | N/A | Active |
---|
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.